Join the Donanemab group to help and get support from people like you.
Donanemab News
FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease
INDIANAPOLIS, July 9, 2025 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended t...
Anti-Amyloid Drug Shows Promise In Preventing Alzheimer's
MONDAY, March 24, 2025 – The best evidence yet that cutting-edge Alzheimer’s disease drugs might indeed ward off the degenerative brain disease has emerged from a small-scale study. An experimental d...
FDA Approves Kisunla (donanemab-azbt) for the Treatment of Early Symptomatic Alzheimer's Disease
INDIANAPOLIS, July 2, 2024 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's ...